Baxter Recalls IV Solutions

News
Article

Baxter voluntarily recalls select lots of IV solutions due to possible particulate matter.

FDA reported on April 9, 2015 that Baxter International has voluntarily recalled select lots of intravenous (IV) solutions for possible particulate matter. The IV solutions include Sodium Chloride Injection, USP, indicated as a source of water and electrolytes and for use as a priming solution in hemodialysis procedures; Dextrose Injection, USP, indicated as a source of water and calories; and Lactated Ringer’s Injection, USP, indicated as a source of water and electrolytes, or as an alkalinizing agent. The recalled lots were distributed in the United States and Bermuda between Jan. 14, 2015 and March 5, 2015.

Baxter personnel discovered the particulates while performing routine maintenance and identified the particulates as material from a solution transmission system pump. The company has not yet received any adverse event reports or complaints.

A full list of recalled lots can be found on FDA’s website.

Source: FDA

Recent Videos
Tore Bergsteiner from MAIN5 details his predictions for how the mega trends will shape the bio/pharma industry in 2025 and beyond.
Roger Viney from ICE Pharma discusses the quality and compliance issues surrounding the use of animal-derived ingredients in the bio/pharma industry.
Tore Bergsteiner from MAIN5 discusses the most pertinent and impactful bio/pharma industry trends from 2024.
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.